Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampyra Extension Study in MS (MS-F203EXT)
NCT00648908Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- Jun 2006
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dalfampridine in multiple sclerosis (MS), sponsored by Acorda Therapeutics. Started Jun 2006; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00648908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00648908.